Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
Cryoport, Inc. filed this Current Report on Form 8-K on February 25, 2015, covering events occurring between February 25, 2015, and March 17, 2015. The filing details a private placement of securities to institutional and accredited investors.
Key Financial Metrics
- Gross Proceeds: $599,648
- Net Proceeds: Approximately $520,144 (after estimated cash offering expenses)
- Securities Issued: 49,971 Units
- Price per Unit: $12.00
- Unit Composition: One share of Class B Preferred Stock and one warrant to purchase eight shares of Common Stock.
- Warrant Terms: Exercise price of $0.50 per share; exercisable immediately through May 31, 2020.
- Placement Agent Fees: 10% commission plus a 3% non-accountable finance fee on gross proceeds, plus up to $5,000 in legal expense reimbursement.
Material Changes
The primary material change is the entry into definitive agreements for the private placement described above. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
Use of Proceeds: Management intends to use the net proceeds for working capital purposes.
Placement Agent Warrants: Emergent Financial Group, Inc. received warrants to purchase three shares of Common Stock at $0.50 per share for each Unit issued.
Regulatory Status: The sale was conducted under exemptions provided by Regulation D and Section 4(2) of the Securities Act of 1933, without a public offering.
Investor Verification Checklist
- Verify the full text of the Subscription Agreements and Warrants filed as Exhibits 10.1 and 4.1 to the Form 8-K dated February 17, 2015.
- Confirm the exact amount of cash offering expenses deducted to reach the net proceeds figure.
- Review the dilution impact of the 49,971 warrants issued to investors and the additional warrants issued to the placement agent.
- Check subsequent filings for the actual utilization of the working capital proceeds.